drugset / Trial / NCT06423703

A Study of Cebranopadol for the Treatment of Acute Pain After Bunionectomy

NCT06423703

Phase 3 Completed 240 enrolled Tris Pharma, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of Cebranopadol for acute pain after a bunionectomy.

Timeline

Start
2024-07-18
Primary completion
2025-01-31
Completion
2025-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Cebranopadol Small molecule
Comparator Oxycodone Other / unclassified

Indications

No indication recorded.